Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
BioCryst Pharmaceuticals Inc(BCRX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BCRX
09/25/2026: BCRX (1-star) is currently NOT-A-BUY. Pass it for now.
BioCryst Pharmaceuticals is a mid-sized biotechnology company currently focused on the commercialization of ORLADEYO, an oral treatment for hereditary angioedema. Its main strength lies in its ability to offer a convenient, once-daily pill in a market historically dominated by injectable alternatives. The investment story centers on capturing greater market share through increased patient adoption and international expansion. Risks include high competition from larger industry players, execution risks in scaling revenue, and the need to manage cash burn until profitability is achieved. This stock may suit growth-oriented investors with a high risk tolerance who are looking for exposure to targeted rare disease treatments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company represents a high-growth phase as it expands market share for its flagship commercial product. |
| Momentum investor | Mixed fit | Momentum appeal depends heavily on positive clinical or commercial news cycles and sustained price uptrends. |
| Value investor | Weak fit | BioCryst is not a value play due to its ongoing net losses and lack of traditional valuation metrics like P/E ratios. |
| Dividend investor | Weak fit | The company does not pay a dividend and focuses entirely on reinvestment. |
| Low-risk investor | Weak fit | Biotechnology volatility and reliance on a single commercial product create high risk for conservative investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks often swing based on clinical trial results and regulatory announcements. |
| Valuation risk | Medium / high | Future growth expectations are baked into the price, leaving little room for error. |
| Competition risk (HAE therapy) | Medium / high | Well-funded competitors can quickly erode market share with new, superior treatments. |
| Business quality | Medium | While the product is effective, the company is still in the early stages of establishing financial self-sufficiency. |
| Dividend income | Low / none | This is a growth-stage company with no current plans to return cash to shareholders. |
| Execution risk | Medium / high | Success depends on the ongoing ability to grow sales and navigate the complex healthcare reimbursement system. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -44.98% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.18B USD | Price to earnings Ratio - | 1Y Target Price 20.64 |
Price to earnings Ratio - | 1Y Target Price 20.64 | ||
Volume (30-day avg) 4.1M shares | Beta 0.56 | 52 Weeks Range 6.00 - 11.22 | Updated Date 09/25/2026 |
52 Weeks Range 6.00 - 11.22 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.39 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Revenue | Primary revenue is generated through the sale of ORLADEYO in the US and international markets. | The company's success is almost entirely tied to how many patients take its daily oral pill. |
| Collaboration and Licensing | Fees from research collaborations and potential future licensing agreements. | This is a secondary source of funds, often sporadic and tied to R&D milestones. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 14.49 | Enterprise Value 2.63B | Price to Sales(TTM) 2.31 |
Enterprise Value 2.63B | Price to Sales(TTM) 2.31 | ||
Enterprise Value to Revenue 2.79 | Enterprise Value to EBITDA 7.17 | Shares Outstanding 255.54M | Shares Floating 222.32M |
Shares Outstanding 255.54M | Shares Floating 222.32M | ||
Percent Insiders 1.28 | Percent Institutions 105.34 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About BioCryst Pharmaceuticals Inc
Exchange NASDAQ | Headquarters Durham, NC, United States | ||
IPO Launch date 1994-03-03 | CEO, President & Director Mr. Charles K. Gayer | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 435 | Website https://www.biocryst.com |
Full time employees 435 | Website https://www.biocryst.com | ||
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.